United Therapeutics Corp

UTHR

Equity

ISIN US91307C1027 / Valor 848383

NASDAQ (2024-11-20)

USD 364.33+1.00%

United Therapeutics Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

United Therapeutics Corp is a biotechnology company that focuses on the development and commercialization of innovative therapies for patients with chronic and life-threatening conditions, particularly in the field of pulmonary hypertension.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

United Therapeutics Corp's total revenues for the second quarter of 2024 grew by 20% year-over-year, reaching $714.9 million compared to $596.5 million in the second quarter of 2023. This significant increase was driven by strong performance across their product portfolio, particularly Tyvaso.

Net Income

For the second quarter of 2024, United Therapeutics Corp reported a net income of $278.1 million, which represents a 7% increase from the $259.2 million reported in the same quarter of the previous year. This growth in net income reflects the company's effective cost management and revenue growth.

Product Sales

United Therapeutics Corp's Tyvaso product line, including Tyvaso DPI and Nebulized Tyvaso, saw a 25% increase in sales, totaling $398.2 million in the second quarter of 2024. This growth was primarily due to increased quantities sold and price adjustments, driven by the commercial success of Tyvaso DPI.

Research and Development Expenses

Research and development expenses for United Therapeutics Corp in the second quarter of 2024 were $139.6 million, a 57% increase from $89.0 million in the same period of 2023. This rise was mainly due to higher expenditures on drug delivery devices and organ manufacturing projects.

Selling, General, and Administrative Expenses

United Therapeutics Corp's selling, general, and administrative expenses for the second quarter of 2024 increased by 37% to $177.6 million, up from $130.0 million in the second quarter of 2023. The increase was driven by higher legal expenses and personnel costs due to an increase in headcount.

Summarized from source with an LLMView Source

Key figures

59.1%1Y

81.1%3Y

284%5Y

Performance

27.5%1Y

29.2%3Y

32.6%5Y

Volatility